Fundz
Funding, M&A and exec moves matched to your market, guaranteed to pay for itself in a year, or we refund it. See terms for full details.See plans →

Kynexis extends its Series A funding by €40 million, bringing the total to €97 million. The funding, led by Novartis Venture Fund, will support Phase 2 studies for its cognitive medicine.

PRIVATEAug 19, 2026•about 5 hours ago

Amount Raised

€40 Million

Round Type

Series A

North HollandBiotechnologyHealth CareTherapeutics

Investors

Sunstone Life Science VenturesYsios CapitalForbionNovartis Venture Fund

Description

Kynexis announced the closing of a €40 million Series A extension, increasing total Series A financing to €97 million. The financing was led by Novartis Venture Fund, with participation from existing investors. It will support close-out activities for a Phase 2 study of KYN-5356 for cognitive impairment. The company is also preparing for registrational studies and aims to advance towards additional cognitive disorders.

Company Information

Company

Kynexis

Location

North Holland, Netherlands

About

Kynexis is a clinical-stage biotechnology company focused on improving cognition for people living with brain diseases. The company is advancing KYN-5356, a potential first-in-class investigational medicine aimed at treating cognitive impairment associated with schizophrenia. Kynexis aims to address cognitive dysfunction across multiple neurological and neurodegenerative disorders. The company is on track to report topline results from its Phase 2 study by the end of 2026.

Don't miss Kynexis's next move

Get an email the moment Kynexis raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Kynexis's next move

Learn about Strategic plan

Funding Insights

Based on industry data
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months
Monthly burn rate benchmark
47% of Series A startups spend $400k or more per month on operations
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Kynexis raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.